Journal of Renal Nutrition
Volume 12, Issue 4 , Pages 248-255 , October 2002

A new approach to classifying malnutrition in the hemodialysis patient

  • Aura O'Keefe, RD

      Affiliations

    • San Diego Dialysis–National City, National City, CA.
    • ,
  • Nancy W. Daigle, CSR, RD

      Affiliations

    • San Diego Dialysis–Chula Vista South, San Diego, CA.

References 

  1. Stenvinkel P, Heimburger O, Lindholm B, et al.  Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis. Nephrol Dial Transplant. 2000;15:953–960
  2. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif. 2001;19:143–151
  3. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol. 2001;12:1549–1557
  4. Kaysen GA, Chertow GM, Adhikarla R, et al.  Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int. 2001;60:333–340
  5. Bistrian B. Interaction between nutrition and inflammation in end-stage renal disease. Blood Purif. 2000;18:333–336
  6. Kaysen GA. Malnutrition and the acute-phase reaction in dialysis patients—how to measure and how to distinguish. Nephrol Dial Transplant. 2000;15:1521–1524
  7. Kaysen GA. C-reactive protein: A story half told. Semin Dial. 2000;13:143–146
  8. Kaysen GA. Interpretation of plasma protein measurements in end-stage renal disease. Blood Purif. 2000;18:337–342
  9. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?. Kidney Int. 2001;59:407–414
  10. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis. 1998;32(suppl 4):S-118–S-125
  11. Yeun JY. Clinical utility of C-reactive protein measurements. Semin Dial. 2000;13:56–57
  12. Bergstrom J, Lindholm B, Lacson E, et al.  What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?. Semin Dial. 2000;13:163–164
  13. Stenvinkel P, Heimburger O, Paultre F, et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
  14. Drueke TB, Khoa N, Massy ZA, et al.  Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int. 2001;59(suppl):S-114–S-119
  15. Bistrian B, Carey LA. Impact of inflammation on nutrition, iron status, and erythropoietin responsiveness in ESRD patients. Nephrol Nurs J. 2000;27:616–621
  16. Jern NA, VanBeber AD, Gorman MA, et al.  The effects of zinc supplementation on serum zinc concentration and protein catabolic rate in hemodialysis patients. J Renal Nutr. 2000;10:148–153
  17. Balzer C. Nutrition supplementation in end-stage renal disease: Are we being too conservative?. Dial Transplant. 2001;30:387–390
  18. Beto JA. Which diet for which renal failure: Making sense of the options. J Am Diet Assoc. 1995;95:898–903
  19. Buccianti G, Bamonti CF, Patrosso C, et al.  Reduction of the homocysteine plasma concentration by intravenously administered folinic acid and vitamin B (12) in uraemic patients on maintenance haemodialysis. Am J Nephrol. 2001;21:294–299
  20. Crawford JF, Rosenthal AF, Spears C, et al.  Normalization of homocysteine in dialysis patients by directed repletion, with apparent reduction of access thrombosis. Dial Transplant. 2001;30:512–514 516-521
  21. Descombes E, Hanck AB, Fellay G. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int. 1993;43:1319–1328
  22. Dierkes J, Domrose U, Bosselmann KP, et al.  Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease. J Renal Nutr. 2001;11:67–72
  23. Descombes E, Boulat O, Perriard F, et al.  Water soluble vitamin levels in patients undergoing high-flux hemodialysis and receiving long-term oral postdialysis vitamin supplementation. Artif Organs. 2000;24:773–778
  24. Descombes E, Boulat O, Bersier LF, et al.  Difference in the homocysteine-lowering effect of folic acid in haemodialysis patients with and without occlusive vascular disease. Nephrol Dial Transplant. 2001;16:585–589
  25. Gonenc A, Atak Y, Orman MN, et al.  Lipid perioxidation and antioxidant systems in hemodialysis patients. Dial Transplant. 2002;31:88–91 94-96
  26. Hegbrant J, Bengtsson UH. Vitamin C and E as antioxidants in hemodialysis patients. Int J Artif Organs. 1999;22:69–73
  27. Manns B, Hyndman EB, Parsons H, et al.  Oral vitamin B12 and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia. Kidney Int. 2001;59:1103–1109
  28. Nakayama H, Akiyama S, Inagaki M, et al.  Dehydroascorbic acid and oxidative stress in hemodialysis patients. Nephrol Dial Transplant. 2001;16:574–579
  29. Sepe V, Ottone S, Patrucco G, et al.  Effectiveness of oral supplements of folates, vitamin B12 and B6 in hemodialysis patients. Preliminary results after 5 months of follow-up. Minerva Urol Nefrol. 2001;53:57–59
  30. Tremblay R, Bonnardeaux A, Geadah D, et al.  Hyperhomocysteinemia in hemodialysis patients: Effect of 12-month supplementation with hydrosoluble vitamins. Kidney Int. 2000;58:851–858
  31. Boaz M, Smetana S, Weinstein T, et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomized placebo-controlled trial. Lancet North Am Ed. 2000;356:1213–1218
  32. Islam KN, O'Byrne D, Devaraj S, et al.  Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis. 2000;150:217–224
  33. Jackson P, Loughrey CM, Lightbody JH, et al.  Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem. 1995;41:1135–1138
  34. Maccarrone M, Meloni C, Manca-di-Villahermosa S, et al.  Vitamin E suppresses 5-lipoxygenase-mediated oxidative stress in peripheral blood mononuclear cells of hemodialysis patients regardless of administration route. Am J Kidney Dis. 2001;37:964–969
  35. Morena M, Cristol J-P, Canaud B. Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance?. Blood Purif. 2000;18:191–199
  36. Roob JM, Khoschsorur G, Tiran A, et al.  Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol. 2000;11:539–549
  37. Weiss M. Vitamin E for dialysis patients. Semin Dial. 2000;14:71–72
  38. Peck LW. Role of omega-3 (n-3) fatty acids in treatment of chronic renal failure. Renal Nutrition Forum. 2000;19:6-8–6-12, 14
  39. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivi perioxidation of LDL in dialysis patients. J Am Soc Nephrol. 1999;10:2177–2184
  40. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Renal Nutr. 2000;10:191–195
  41. Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on homeostasis, blood pressure, and lipid profile of dialysis patients. J Am Soc Nephrol. 1992;2:1634–1639
  42. Rolf N, Tenschert W, Lison AE. Results of a long-term administration of omega-3 fatty acids in haemodialysis patients with dyslipoproteinaemia. Nephrol Dial Transplant. 1990;5:797–801
  43. Khajehdehi P. Effect of vitamins on the lipid profile of patients on regular dialysis. Scand J Urol Nephrol. 2000;34:62–66
  44. Galli F, Varga Z, Balla J, et al.  Vitamin E, lipid profile, and perioxidation in hemodialysis patients. Kidney Int. 2001;59(suppl 78):S-148–S-154
  45. Handelman G. Evaluation of oxidant stress in dialysis patients. Blood Purif. 2000;18:343–349
  46. Morena M, Cristol JP, Bosc JY, et al.  Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant. 2002;17:422–427
  47. Stenvinkel P, Andersson P, Wang T, et al.  Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?. J Intern Med. 1999;246:503–507
  48. de Cavanagh EMV, Ferder L, Carrasquedo F, et al.  Higher levels of anti-oxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients. Am J Kidney Dis. 1999;34:445–455

☆ Address reprint requests to Aura O'Keefe, RD, San Diego Dialysis–National City, 303 West 26th St, National City, CA 91950.

PII: S1051-2276(02)00022-5

Journal of Renal Nutrition
Volume 12, Issue 4 , Pages 248-255 , October 2002

Article Tools

* Image Usage & Resolution